Chemotherapy Induced Peripheral Neuropathy Pipeline Review, H2 2016
Global Markets Direct’s, Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016′, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report on Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2016 addition with 44 market data tables and 14 figures, spread across 128 pages is http://www.rnrmarketresearch.com/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
Drugs Profile Discussed in this Research:
(amitriptyline + ketamine hydrochloride), AM-1710 , AXPN-02, BR-297, cannabidiol, dimiracetam Drugs for Peripheral Neuropathy, DX-0332, E-2072 , HM-01,, ketoprofen KP-544 , KRN-5500, LM11A-31BHS, Lpathomab, MR-309, NB-2111 , NRX-2922 , NT-24336, PAN-811 , PGN-503, piclidenoson, pirenzepine hydrochloride , PP-095, Q-201, Small Molecule for Pain, Neuropathy, Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy, Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy , Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy, Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy, SPI-205, Tetrodotoxin, U-2902, XT-150
Achelios Therapeutics, Advinus Therapeutics Ltd, Amplyx Pharmaceuticals, Can-Fite BioPharma Ltd., DermaXon, Eisai Co., Ltd., Immune Pharmaceuticals Inc., INSYS Therapeutics, Inc., KPI Therapeutics, Inc., Krenitsky Pharmaceuticals Inc., Laboratorios Del Dr. Esteve S.A. Lpath, Inc., MAKScientific, LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc., Nemus Bioscience, Inc., Neurocentrx Pharma Ltd., Panacea Pharmaceuticals, Inc., PeriphaGen, Inc., PharmatrophiX, Inc., PledPharma AB, Sova Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Virobay Inc., WEX Pharmaceuticals Inc.,
Inquire before buying for this report
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=696571(This is a premium report price at US$2000 for a single user PDF license).
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market